Completed PHASE2 INTERVENTIONAL 4-arm NCT01686503

Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects (IDIPV)

Comparison of the Immunogenicity of Various Inactivated Polio Vaccine Booster Doses by Intradermal vs. Intramuscular Routes in HIV-Infected Subjects

Sponsor: Eastern Virginia Medical School

Conditions Polio Immunity

Interventions IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose

Updated 8 times since 2017 Last updated: Jan 22, 2015 Started: Sep 30, 2012 Primary completion: Aug 31, 2013 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01686503, this PHASE2 trial focuses on Polio Immunity and remains completed. Sponsored by Eastern Virginia Medical School, it has been updated 8 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Dec 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eastern Virginia Medical School
NanoPass Technologies Ltd

Data source: Eastern Virginia Medical School

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Norfolk, United States